Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Oral Cyclophosphamide


  • Please log in to reply
No replies to this topic

#1 Jeannie McClelland

Jeannie McClelland

    Senior Gold Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 1,706 posts
  • Location:in the Rocky Mountains of the USA

Posted 07 January 2009 - 06:04 AM

Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. Results from the recent Scleroderma Lung Study (SLS) show that oral cyclophosphamide (CYC) is better than placebo in preventing the progression of scleroderma-related interstitial lung disease (SSc-ILD) at 12 months but is associated with adverse events. Also, the long-term balance of risk and benefit remains unclear. D Khanna. (Sage Journals) Medical Decision Making, Vol. 28, No. 6, 926-937 (2008). (Also see: Pulmonary Fibrosis)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Jeannie McClelland
(Retired) ISN Director of Support Services
(Retired) ISN Sclero Forums Manager
(Retired) ISN Blog Manager
(Retired) ISN Assistant News Guide
(Retired) ISN Artist
International Scleroderma Network